IDXX Stock Analysis
💡 Quick Answer
Across 4 APEX technical signals, IDXX is currently split between bullish and bearish readings — 0 bullish, 0 bearish as of 2026-06-11. Run a live analysis to see the current composite score.
IDXX is a premium-quality compounder with ATR of 3-5%, trading at a premium multiple justified by its recurring diagnostics revenue and dominant market position. Post-earnings moves of 7-11% are typical.
IDEXX Laboratories is the world's leading veterinary diagnostics company, manufacturing in-clinic analyzers (blood, urine, chemistry testing equipment for veterinary practices), rapid test kits, and reference laboratory services. Its installed base of 100,000+ diagnostic instruments in veterinary clinics globally generates a highly recurring consumable and service revenue stream. Similar to Thermo Fisher's lab instrument model in human healthcare. IDEXX also provides practice management software used by 40%+ of U.S. veterinary practices.
Why Do Traders Watch IDXX?
IDXX is a premium-quality compounder with ATR of 3-5%, trading at a premium multiple justified by its recurring diagnostics revenue and dominant market position. Post-earnings moves of 7-11% are typical. IDXX is sensitive to veterinary visit volumes and pet population trends. When pet owners reduce discretionary vet spending (wellness exams, preventive care), IDXX's consumable revenue declines. The company benefits from the same pet humanization trend as ZTS.
Is IDXX a Buy Right Now? Current Signal Readings
IDEXX's 100,000+ installed diagnostic instruments each generate $15,000-25,000 per year in consumable revenue (test cartridges, reagents, controls) that recur as long as the instrument operates. Consumable revenue growth above 10%. Driven by higher testing frequency per instrument and new analyzer placements. Is the most reliable IDXX earnings indicator, visible 60-90 days in advance from instrument placement data.
Once a veterinary practice installs an IDEXX Catalyst or ProCyte analyzer, switching costs are extremely high. The practice staff is trained on IDEXX instruments and the practice management software is integrated with IDEXX diagnostic results. This creates 95%+ instrument retention and a captive consumable revenue base that compounds as new practices are added each year.
IDXX's consistent 10-15% revenue growth and premium multiple sustain a high RSI floor. RSI dips to 45-50 during periods of concern about vet visit volumes or broader consumer spending cuts. While instrument placements remain steady. Have been reliable IDXX entry points for traders with 3-6 month holding horizons seeking high-quality healthcare growth.
IDEXX's reference laboratory business. Providing complex diagnostic testing for cases that require more analysis than in-clinic instruments can perform. Is growing at 12-15% annually. Each IDEXX reference lab acquired or built expands test menu depth and geographic coverage, creating a diagnostics ecosystem that competitors would need 10+ years and billions of dollars to replicate.
📋 IDXX Key Stats for Traders
APEX combines RSI, MACD, Fibonacci, Volume, and 4 more signals into one composite score in under 30 seconds.
Analyze IDXX Free →